Sage Therapeutics Inc. Announces Delisting from Nasdaq Following Merger Completion
Sage Therapeutics Inc. has announced its delisting from The Nasdaq Global Market following a merger. The company will halt trading of its shares on July 30, 2025, and has requested Nasdaq to suspend trading and file for deregistration with the SEC. Sage plans to submit a Form 15 to terminate its common stock registration and suspend its reporting obligations under the Securities Exchange Act of 1934.
Sage Therapeutics Inc. has announced its decision to delist its shares from The Nasdaq Global Market following the consummation of a merger. The company informed the Nasdaq Stock Market LLC of its intent to halt trading of the shares as of July 30, 2025, and subsequently requested Nasdaq to suspend trading and file for deregistration with the SEC. As a result, Sage Therapeutics will no longer be listed on Nasdaq and plans to submit a Form 15 to terminate its common stock registration and suspend its reporting obligations under the Securities Exchange Act of 1934. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sage Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-170187), on July 31, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
